Agile Therapeutics is the pharmaceutical company developing contraceptive healthcare products for women. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive patch.

In addition to Twirla, Agile is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of the Company's product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

TypePublic
HQPrinceton, US
Founded1997
Size (employees)19 (est)+12%
Websiteagiletherapeutics.com
Agile Therapeutics was founded in 1997 and is headquartered in Princeton, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Agile Therapeutics

Al Altomari

Al Altomari

President & CEO & Board ofDirectors
Scott Coiante

Scott Coiante

CFO
C.Gregory Arnold

C.Gregory Arnold

Vice President of Manufacturing
Robert G.Conway

Robert G.Conway

Chief Development Officer, Vice President, Operations
Elizabeth Garner

Elizabeth Garner

Senior Vice President and Chief Medical Officer
Show more

Agile Therapeutics Office Locations

Agile Therapeutics has an office in Princeton
Princeton, US (HQ)
101 Poor Farm Rd
Show all (1)
Report incorrect company information

Agile Therapeutics Financials and Metrics

Agile Therapeutics Revenue

USD

Net income (Q2, 2018)

(12.2 m)

EBIT (Q2, 2018)

(12.2 m)

Market capitalization (20-Sep-2018)

12.2 m

Closing stock price (20-Sep-2018)

0.4

Cash (30-Jun-2018)

22.5 m
Agile Therapeutics's current market capitalization is $12.2 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

5.2 m7.5 m8.8 m12.4 m

R&D expense

13.4 m25.6 m20.9 m14.4 m

Operating expense total

18.5 m33.1 m29.7 m26.8 m

EBIT

(18.5 m)(33.1 m)(29.7 m)(26.8 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

1.1 m1.4 m1.6 m1.8 m1.8 m2.1 m2.3 m2.2 m2.4 m3.2 m3.1 m5.4 m

R&D expense

2.4 m4.6 m5.4 m6.2 m7.2 m4.9 m5.6 m4.9 m4.7 m3.8 m4 m6.4 m

Operating expense total

3.5 m6 m7 m8 m9 m7 m7.8 m7.1 m7.1 m7 m6.7 m7 m12.2 m

EBIT

(3.5 m)(6 m)(7 m)(8 m)(9 m)(7 m)(7.8 m)(7.1 m)(7.1 m)(7 m)(6.7 m)(7 m)(12.2 m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

40.2 m34.4 m48.8 m36 m

Accounts Receivable

539 m

Current Assets

41 m38.1 m51.5 m36.7 m

PP&E

12 m12.3 m12.3 m13.9 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

53.5 m45.7 m53.9 m46.4 m39.4 m65.5 m59.2 m51.7 m41.7 m33.9 m43.8 m28.3 m22.5 m

Inventories

1.6 m

Current Assets

54.2 m47 m54.4 m47.2 m40.7 m68.5 m61.3 m54.8 m44.3 m34.5 m45 m29 m22.7 m

PP&E

12.3 m12.3 m12.3 m12.3 m12.8 m13.9 m13.9 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(16.1 m)(30.3 m)(28.7 m)(28.3 m)

Depreciation and Amortization

12.6 k18 k19 k23 k

Inventories

(2.3 m)(1.2 m)922 k

Accounts Payable

2.6 m1.3 m362 k(2.5 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(2.9 m)(9.2 m)(8.5 m)(17 m)(26.4 m)(7.3 m)(15.7 m)(23.5 m)(7.5 m)(15 m)(7.1 m)(6.8 m)(12.2 m)

Depreciation and Amortization

5 k7.7 k5 k10.1 k14.3 k4 k9 k14 k5 k11 k6 k12 k

Inventories

1.6 m

Accounts Payable

1.6 m2.2 m724.3 k1.2 m3 m(771 k)(768 k)(648 k)348 k(1.2 m)2.8 m(269 k)(644 k)
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics

Agile Therapeutics Operating Metrics

FY, 2016

Patents (foreign)

45

Phase I Trials Products

3

Phase II Trials Products

1

Phase III Trials Products

1
Show all operating metrics
Report incorrect company information

Agile Therapeutics News and Updates

Agile Therapeutics Reports Second Quarter 2018 Financial Results

Cash Expected to Enable Company to Fund Operations into Second Quarter 2019

Agile Therapeutics exploring funding options after FDA meeting

May 18 (Reuters) - Agile Therapeutics Inc said on Friday it was looking for ways to fund operations after a meeting with the U.S. health regulator raised the possibility of a new clinical trial to test its stick-on contraceptive patch, Twirla.
Report incorrect company information

Agile Therapeutics Company Life and Culture

Report incorrect company information